BioSpace News Archive

Amphivena Therapeutics , a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that

On November 20 th , S-Alpha Therapeutics (“S-Alpha” Seung Eun Choi, CEO), a digital therapeutics startup, completed a $2.7 Million USD (3 Billion KRW) seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. This seed round follows an initial strategic investment from LegoChem Biosciences in February 2020. This press release features multimedia. View the full release

- First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes - Abbott and eMed™ expect to deliver and administer 30 million BinaxNOW™ tests in the first quarter of 2021, with an additional 90 million in the second quarter - $25 cost for the test and service is the lowest available for at-home testing, which supports the home user to ensure a successful testing process

Children’s Minnesota is pleased to announce the promotion of James C. Burroughs II from senior director to vice president, chief equity and inclusion officer, effective Jan. 9, 2021.

CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL)

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform.

Aerus Medical formally announced the start of a double-blind two-year clinical study to evaluate the impact the Aerus Medical Guardian with ActivePure Technology can have on reducing nosocomial infections, or healthcare-associated infections, also known as HAIs, from surgical operating room procedures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005947

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon’s patent rights for the compound. LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon. “In line with our realignment aroun

Matrix Medical Network ® (Matrix) today announced the completion of the integration of Biocerna, a state-of-the-art CLIA-certified and CAP-accredited laboratory dedicated to delivering clinical

The Prostate Cancer Foundation (PCF) today announced the Class of 2020 Young Investigator Award recipients totaling $6 million in funding for innovative prostate cancer research. PCF Young Investig